Whether Opioids Are Factor That Induced POD?

Sponsor
Zhejiang Cancer Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05596071
Collaborator
(none)
130
1
2
54.2
2.4

Study Details

Study Description

Brief Summary

The purpose of this study was to investigate whether perioperative use of low doses of opioids could reduce postoperative delirium .

Condition or Disease Intervention/Treatment Phase
  • Drug: Sufentanil Citrate
  • Drug: Ropivacaine 0.75% Injectable Solution
  • Procedure: Epidural catheter
N/A

Detailed Description

Postoperative delirium (POD) is a common postoperative complication of the elderly caused by a variety of factors. POD is an acute neuropsychiatric disorder characterized by disturbance of attention consciousness and cognitive function fluctuation, and more than 40% of elderly patients have symptoms of hypoactivity POD.The incidence of POD is as high as 17% to 61% in patients with neurocognitive impairment and patients undergoing complex or emergency surgery, which usually occurs between 1 and 3 days after surgery. POD will lead to prolonged hospital stay, functional impairment and even death. How to prevent and treat POD is an urgent clinical problem to be solved at present.

Opiates are commonly used perioperative sedatives and analgesics, which may be associated with the occurrence of postoperative POD in elderly patients and increase the risk of POD. It is not clear whether perioperative use of low doses of opioids could reduces the incidence of POD in elderly patients. In this study, reducing-opioids anesthesia was defined as the use of 1/3 of the conventional opioid dose to observe whether reducing-opioids anesthesia affected the incidence of POD in elderly patients undergoing gastric cancer surgery

Study Design

Study Type:
Interventional
Actual Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Screening
Official Title:
Whether Opioids Are Factor That Induced Postoperative Delirium?
Actual Study Start Date :
Jun 25, 2016
Actual Primary Completion Date :
Jul 15, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sufentanyl+Epidural analgesia

Combined use of sufentanil and ropivacaine for intraoperative and postoperative analgesia

Drug: Sufentanil Citrate
Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
Other Names:
  • Sufentanil
  • Drug: Ropivacaine 0.75% Injectable Solution
    Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
    Other Names:
  • Ropivacaine
  • Procedure: Epidural catheter
    Intraoperative and postoperative analgesia

    Sham Comparator: Epidural analgesia

    Only use of ropivacaine for intraoperative and postoperative analgesia

    Drug: Ropivacaine 0.75% Injectable Solution
    Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
    Other Names:
  • Ropivacaine
  • Procedure: Epidural catheter
    Intraoperative and postoperative analgesia

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of postoperative delirium [3 days after surgery]

      confusion assessment method for the ICU(CAM-ICU)

    2. Incidence of postoperative delirium [3 days after surgery]

      Richmond agitation and sedation scale(RASS), the RASS score was divided into 10 sedation scales, ranging from +4 to -5, representing the patient's degree from "aggressive" to "unconscious," with each score corresponding to a state of consciousness. When the RASS score was ≥-3, the CAM-ICU assessment was performed.

    Secondary Outcome Measures

    1. Visual analogue scale(VAS) [3 days after surgery]

      VAS is a scale of 11 numbers ranging from 0 to 10, with 0 representing no pain and 10 representing the most pain. Patients choose one of the 11 numbers to represent the pain level according to their own pain. 0: no pain; Less than 3 points: mild pain, tolerable; 4-6 points: the patient's pain and affect sleep, still tolerable; 7-10: Patients have increasing pain, pain is unbearable, affect appetite, affect sleep.

    2. Anaesthesia related adverse event [3 days after surgery]

      Nausea and vomiting

    3. blood pressure [3 days after surgery]

      Hypertension or hypotension was defined as an increase or decrease in mean arterial pressure of more than 30% at baseline

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients' age ≥65 years

    • Underwent elective radical gastrectomy

    Exclusion Criteria:
    • Mini-Mental Scale Test (MMSE) Exclusion criteria: illiteracy <18, primary school <21, junior school and above <25

    • Preoperative clear systems and spiritual history of neurological disease or long-term use of sedatives or antidepressants

    • History of alcohol abuse or a history of drug dependence

    • Have brain surgery or trauma

    • Cannot with the completion of tests of Postoperative Cognitive Dysfunction

    • Refused to participate in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhejiang Cancer Hospital Hangzhou Zhejiang China 310022

    Sponsors and Collaborators

    • Zhejiang Cancer Hospital

    Investigators

    • Principal Investigator: chaoqun Fei, Zhejiang Cancer Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fang Jun, Director, Zhejiang Cancer Hospital
    ClinicalTrials.gov Identifier:
    NCT05596071
    Other Study ID Numbers:
    • 2016-10-10
    First Posted:
    Oct 27, 2022
    Last Update Posted:
    Oct 27, 2022
    Last Verified:
    Oct 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fang Jun, Director, Zhejiang Cancer Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 27, 2022